CUR Neuralstem, Inc.

6.33
+0.37  (6%)
Previous Close 5.96
Open 6.00
Price To book 7.16
Market Cap 75.32M
Shares 11,899,000
Volume 220,255
Short Ratio 7.60
Av. Daily Volume 93,966

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Ongoing.
NSI-566
Motor deficits due to ischemic stroke
Phase 1b to be initiated 2016
NSI-189
Cognitive deficit in schizophrenia
Phase 2 completion of dosing announced May 17, 2017. Data are due 3Q 2017.
NSI-189
Major depressive disorder
Phase 2 data released early March 2015. A larger controlled Phase 2 trial is dependent on funding
NSI-566
Amyotrophic lateral sclerosis (Lou Gehrig's)

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 17930587
  2. 424B2 - Prospectus [Rule 424(b)(2)] 17930586
  3. EFFECT - Notice of Effectiveness 17928816
  4. S-3/A [Amend] - Registration statement under Securities Act of 1933 17923533
  5. S-3 - Registration statement under Securities Act of 1933 17900791
  6. D - Notice of Exempt Offering of Securities 17881905
  7. 8-K - Current report 17879635
  8. 8-K - Current report 17866676
  9. 8-K - Current report 17853691
  10. 8-K - Current report 17839561